Unknown

Dataset Information

0

Rosiglitazone accelerates wound healing by improving endothelial precursor cell function and angiogenesis in db/db mice.


ABSTRACT: Background & Aims:Endothelial precursor cell (EPC) dysfunction is one of the risk factors for diabetes mellitus (DM) which results in delayed wound healing. Rosiglitazone (RSG) is a frequently prescribed oral glucose-lowering drug. Previous studies have shown the positive effects of RSG on ameliorating EPC dysfunction in diabetic patients. Interestingly, knowledge about RSG with regard to the wound healing process caused by DM is scarce. Therefore, in this study, we investigated the possible actions of RSG on wound healing and the related mechanisms involved in db/db diabetic mice. Methods:Db/db mice with spontaneous glucose metabolic disorder were used as a type 2 DM model. RSG (20 mg/kg/d, i.g.,) was administered for 4 weeks before wound creation and bone marrow derived EPC (BM-EPC) isolation. Wound closure was assessed by wound area and CD31 staining. Tubule formation and migration assays were used to judge the function of the BM-EPCs. The level of vascular endothelial growth factor (VEGF), stromal cell derived factor-1? (SDF-1?) and insulin signaling was determined by ELISA. Cell viability of the BM-EPCs was measured by CCK-8 assay. Results:RSG significantly accelerated wound healing and improved angiogenesis in db/db mice. Bioactivities of tube formation and migration were decreased in db/db mice but were elevated by RSG. Level of both VEGF and SDF-1? was increased by RSG in the BM-EPCs of db/db mice. Insulin signaling was elevated by RSG reflected in the phosphorylated-to-total AKT in the BM-EPCs. In vitro, RSG improved impaired cell viability and tube formation of BM-EPCs induced by high glucose, but this was prevented by the VEGF inhibitor avastin. Conclusion:Our data demonstrates that RSG has benefits for wound healing and angiogenesis in diabetic mice, and was partially associated with improvement of EPC function through activation of VEGF and stimulation of SDF-1? in db/db mice.

SUBMITTER: Zhou G 

PROVIDER: S-EPMC6800979 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

Rosiglitazone accelerates wound healing by improving endothelial precursor cell function and angiogenesis in <i>db/db</i> mice.

Zhou Guoliang G   Han Xue X   Wu Zhiheng Z   Shi Qiaojuan Q   Bao Xiaogang X  

PeerJ 20191017


<h4>Background & aims</h4>Endothelial precursor cell (EPC) dysfunction is one of the risk factors for diabetes mellitus (DM) which results in delayed wound healing. Rosiglitazone (RSG) is a frequently prescribed oral glucose-lowering drug. Previous studies have shown the positive effects of RSG on ameliorating EPC dysfunction in diabetic patients. Interestingly, knowledge about RSG with regard to the wound healing process caused by DM is scarce. Therefore, in this study, we investigated the poss  ...[more]

Similar Datasets

| S-EPMC7476113 | biostudies-literature
| S-EPMC5360971 | biostudies-literature
| S-EPMC1698814 | biostudies-other
| S-EPMC7736285 | biostudies-literature
| S-EPMC8741248 | biostudies-literature
| S-EPMC1892363 | biostudies-literature